相似文献
1
Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria.
Nat Rev Microbiol. 2009 Dec;7(12):864-74. doi: 10.1038/nrmicro2239. Epub 2009 Nov 2.
2
[Combined antimalarial therapy using artemisinin].
Parassitologia. 2004 Jun;46(1-2):85-7.
3
Molecular evidence of increased resistance to anti-folate drugs in Plasmodium falciparum in North-East India: a signal for potential failure of artemisinin plus sulphadoxine-pyrimethamine combination therapy.
PLoS One. 2014 Sep 3;9(9):e105562. doi: 10.1371/journal.pone.0105562. eCollection 2014.
4
Population biology and antimalarial resistance: The transmission of antimalarial drug resistance in Plasmodium falciparum.
Acta Trop. 2005 Jun;94(3):230-40. doi: 10.1016/j.actatropica.2005.04.014.
5
Fighting fire with fire: mass antimalarial drug administrations in an era of antimalarial resistance.
Expert Rev Anti Infect Ther. 2015 Jun;13(6):715-30. doi: 10.1586/14787210.2015.1031744. Epub 2015 Apr 1.
6
Adding artesunate to sulphadoxine-pyrimethamine greatly improves the treatment efficacy in children with uncomplicated falciparum malaria on the coast of Benin, West Africa.
Malar J. 2007 Dec 21;6:170. doi: 10.1186/1475-2875-6-170.
7
Risk of drug resistance in Plasmodium falciparum malaria therapy-a systematic review and meta-analysis.
Parasitol Res. 2017 Feb;116(2):781-788. doi: 10.1007/s00436-016-5353-2. Epub 2016 Dec 27.
8
Sustained efficacy of artesunate-sulfadoxine-pyrimethamine against Plasmodium falciparum in Yemen and a renewed call for an adjunct single dose primaquine to clear gametocytes.
Malar J. 2016 May 27;15(1):295. doi: 10.1186/s12936-016-1344-0.
9
Efficacy of chloroquine and sulphadoxine-pyrimethamine either alone or in combination before introduction of ACT as first-line therapy in uncomplicated Plasmodium falciparum malaria in Jalpaiguri District, West Bengal, India.
Trop Med Int Health. 2011 Aug;16(8):929-35. doi: 10.1111/j.1365-3156.2011.02799.x. Epub 2011 May 12.
10
Efficacy of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria: revisiting molecular markers in an area of emerging AQ and SP resistance in Mali.
Malar J. 2009 Feb 26;8:34. doi: 10.1186/1475-2875-8-34.
引用本文的文献
1
CYP2B6*6 single nucleotide polymorphism among patients with uncomplicated malaria in Adjumani district, Uganda: Implications on efficacy of artemether-lumefantrine.
PLoS One. 2025 Aug 1;20(8):e0322918. doi: 10.1371/journal.pone.0322918. eCollection 2025.
2
Bibliometric and Visualized Analysis of Artemisinin and Its Derivatives in Cancer.
Drug Des Devel Ther. 2025 Jun 30;19:5517-5538. doi: 10.2147/DDDT.S514219. eCollection 2025.
3
single nucleotide polymorphism among patients with uncomplicated malaria in Adjumani district, Uganda: implications on efficacy of artemether-lumefantrine.
medRxiv. 2025 Jun 14:2025.06.13.25329585. doi: 10.1101/2025.06.13.25329585.
4
Human liver organoids are susceptible to Plasmodium vivax infection.
Malar J. 2024 Dec 5;23(1):368. doi: 10.1186/s12936-024-05202-8.
5
Malaria treatment for prevention: a modelling study of the impact of routine case management on malaria prevalence and burden.
BMC Infect Dis. 2024 Nov 8;24(1):1267. doi: 10.1186/s12879-024-09912-x.
6
From Traditional Use to Modern Evidence: The Medicinal Chemistry of Antimalarials from Genus .
Mini Rev Med Chem. 2025;25(3):208-218. doi: 10.2174/0113895575320559240820113540.
7
The Establishment of a Novel In Vitro System for Culturing .
Pathogens. 2024 Jul 4;13(7):565. doi: 10.3390/pathogens13070565.
8
Antiplasmodial potential of isolated xanthones from Mesua ferrea Linn. roots: an in vitro and in silico molecular docking and pharmacokinetics study.
BMC Complement Med Ther. 2024 Jul 25;24(1):282. doi: 10.1186/s12906-024-04580-5.
9
Aryl amino acetamides prevent Plasmodium falciparum ring development via targeting the lipid-transfer protein PfSTART1.
Nat Commun. 2024 Jun 18;15(1):5219. doi: 10.1038/s41467-024-49491-8.
10
Therapeutic efficacy and safety of artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria treatment in Metehara, Central-east Ethiopia.
Malar J. 2024 Jun 12;23(1):184. doi: 10.1186/s12936-024-04991-2.
本文引用的文献
1
Artemisinin-resistant malaria in Asia.
N Engl J Med. 2009 Jul 30;361(5):540-1. doi: 10.1056/NEJMc0900231.
2
Artemisinin resistance in Plasmodium falciparum malaria.
N Engl J Med. 2009 Jul 30;361(5):455-67. doi: 10.1056/NEJMoa0808859.
3
Focusing on quality patient care in the new global subsidy for malaria medicines.
PLoS Med. 2009 Jul 21;6(7):e1000106. doi: 10.1371/journal.pmed.1000106.
4
Stability of peroxide antimalarials in the presence of human hemoglobin.
Antimicrob Agents Chemother. 2009 Aug;53(8):3496-500. doi: 10.1128/AAC.00363-09. Epub 2009 Jun 1.
5
A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria.
Malar J. 2009 May 4;8:89. doi: 10.1186/1475-2875-8-89.
6
Amplification-free Illumina sequencing-library preparation facilitates improved mapping and assembly of (G+C)-biased genomes.
Nat Methods. 2009 Apr;6(4):291-5. doi: 10.1038/nmeth.1311. Epub 2009 Mar 15.
7
Use of high-density tiling microarrays to identify mutations globally and elucidate mechanisms of drug resistance in Plasmodium falciparum.
Genome Biol. 2009 Feb 13;10(2):R21. doi: 10.1186/gb-2009-10-2-r21.
8
In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa.
J Infect Dis. 2009 Mar 1;199(5):750-7. doi: 10.1086/596738.
9
Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.
Antimicrob Agents Chemother. 2009 Apr;53(4):1362-6. doi: 10.1128/AAC.01656-08. Epub 2009 Feb 2.
10
Disruption of a Plasmodium falciparum multidrug resistance-associated protein (PfMRP) alters its fitness and transport of antimalarial drugs and glutathione.
J Biol Chem. 2009 Mar 20;284(12):7687-96. doi: 10.1074/jbc.M806944200. Epub 2008 Dec 31.
Zotero 插件